5 results on '"Pantarotto, Jason"'
Search Results
2. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
- Author
-
Faivre-Finn, Corinne, Snee, Michael, Ashcroft, Linda, Appel, Wiebke, Barlesi, Fabrice, Bhatnagar, Adityanarayan, Bezjak, Andrea, Cardenal, Felipe, Fournel, Pierre, Harden, Susan, Le Pechoux, Cecile, McMenemin, Rhona, Mohammed, Nazia, O'Brien, Mary, Pantarotto, Jason, Surmont, Veerle, Van Meerbeeck, Jan P, Woll, Penella J, Lorigan, Paul, and Blackhall, Fiona
- Subjects
- *
CHEMORADIOTHERAPY , *CANCER treatment , *NON-small-cell lung carcinoma , *RANDOMIZED controlled trials , *FOLLOW-up studies (Medicine) , *TASK performance , *MEDICAL care , *LUNG cancer treatment , *TREATMENT of lung tumors , *ANTINEOPLASTIC agents , *CISPLATIN , *COMPARATIVE studies , *ESOPHAGUS diseases , *ETOPOSIDE , *LONGITUDINAL method , *LUNG cancer , *LUNG tumors , *RESEARCH methodology , *MEDICAL cooperation , *NEUTROPENIA , *RADIATION doses , *RESEARCH , *STATISTICAL sampling , *SURVIVAL , *TUMOR classification , *EVALUATION research , *RADIATION pneumonitis - Abstract
Background: Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard chemoradiotherapy treatment regimen in limited-stage small-cell lung cancer.Methods: The CONVERT trial was an open-label, phase 3, randomised superiority trial. We enrolled adult patients (aged ≥18 years) who had cytologically or histologically confirmed limited-stage small-cell lung cancer, Eastern Cooperative Oncology Group performance status of 0-2, and adequate pulmonary function. Patients were recruited from 73 centres in eight countries. Patients were randomly assigned to receive either 45 Gy radiotherapy in 30 twice-daily fractions of 1·5 Gy over 19 days, or 66 Gy in 33 once-daily fractions of 2 Gy over 45 days, starting on day 22 after commencing cisplatin-etoposide chemotherapy (given as four to six cycles every 3 weeks in both groups). The allocation method used was minimisation with a random element, stratified by institution, planned number of chemotherapy cycles, and performance status. Treatment group assignments were not masked. The primary endpoint was overall survival, defined as time from randomisation until death from any cause, analysed by modified intention-to-treat. A 12% higher overall survival at 2 years in the once-daily group versus the twice-daily group was considered to be clinically significant to show superiority of the once-daily regimen. The study is registered with ClinicalTrials.gov (NCT00433563) and is currently in follow-up.Findings: Between April 7, 2008, and Nov 29, 2013, 547 patients were enrolled and randomly assigned to receive twice-daily concurrent chemoradiotherapy (274 patients) or once-daily concurrent chemoradiotherapy (273 patients). Four patients (one in the twice-daily group and three in the once-daily group) did not return their case report forms and were lost to follow-up; these patients were not included in our analyses. At a median follow-up of 45 months (IQR 35-58), median overall survival was 30 months (95% CI 24-34) in the twice-daily group versus 25 months (21-31) in the once-daily group (hazard ratio for death in the once daily group 1·18 [95% CI 0·95-1·45]; p=0·14). 2-year overall survival was 56% (95% CI 50-62) in the twice-daily group and 51% (45-57) in the once-daily group (absolute difference between the treatment groups 5·3% [95% CI -3·2% to 13·7%]). The most common grade 3-4 adverse event in patients evaluated for chemotherapy toxicity was neutropenia (197 [74%] of 266 patients in the twice-daily group vs 170 [65%] of 263 in the once-daily group). Most toxicities were similar between the groups, except there was significantly more grade 4 neutropenia with twice-daily radiotherapy (129 [49%] vs 101 [38%]; p=0·05). In patients assessed for radiotherapy toxicity, was no difference in grade 3-4 oesophagitis between the groups (47 [19%] of 254 patients in the twice-daily group vs 47 [19%] of 246 in the once-daily group; p=0·85) and grade 3-4 radiation pneumonitis (4 [3%] of 254 vs 4 [2%] of 246; p=0·70). 11 patients died from treatment-related causes (three in the twice-daily group and eight in the once-daily group).Interpretation: Survival outcomes did not differ between twice-daily and once-daily concurrent chemoradiotherapy in patients with limited-stage small-cell lung cancer, and toxicity was similar and lower than expected with both regimens. Since the trial was designed to show superiority of once-daily radiotherapy and was not powered to show equivalence, the implication is that twice-daily radiotherapy should continue to be considered the standard of care in this setting.Funding: Cancer Research UK (Clinical Trials Awards and Advisory Committee), French Ministry of Health, Canadian Cancer Society Research Institute, European Organisation for Research and Treatment of Cancer (Cancer Research Fund, Lung Cancer, and Radiation Oncology Groups). [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
3. Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists.
- Author
-
Dudani, Shaan, Leighl, Natasha B., Ho, Cheryl, Pantarotto, Jason R., Zhu, Xiaofu, Zhang, Tinghua, and Wheatley-Price, Paul
- Subjects
- *
NON-small-cell lung carcinoma , *CANCER treatment , *ONCOLOGIC surgery , *CHEMORADIOTHERAPY , *RANDOMIZED controlled trials , *DIAGNOSIS , *PATIENTS - Abstract
Background and objectives Standard management of stage II non-small cell lung cancer (NSCLC) is surgery, often followed by adjuvant chemotherapy. However, some patients do not undergo surgery for various reasons. The optimal non-surgical management of stage II NSCLC is undefined. We surveyed Canadian oncologists to understand current practices. Materials and methods Canadian oncologists specializing in the management of lung cancer were invited by email to complete an anonymous, online survey developed by the research team. Physician demographics were recorded. Physicians were asked to comment on their practice and make treatment choices in eight clinical scenarios of inoperable stage II NSCLC. Results Responses were received from 81/194 physicians (42% response rate), 57% medical and 42% radiation oncologists. Most physicians (90%) had a practice with at least 25% lung cancer patients and 85% were based at an academic institution. Across eight clinical patient scenarios, radical therapy was selected 79–98% of the time. Radical radiotherapy alone and concurrent chemoradiotherapy were the preferred options for these patients, while sequential chemoradiation was less favoured. Nodal status (N0 vs N1) did not influence choice of therapy (p 0.31), but the reason for patient inoperability did (p < 0.0001). There was no significant difference in choice of therapy when comparing responses between medical vs radiation oncologists, academic vs community physicians, and physicians with high vs low proportion of lung cancer patients. Conclusion Most lung cancer physicians manage inoperable stage II NSCLC patients with curative intent, but consensus on how to optimally employ radiotherapy and/or chemotherapy is lacking. Future prospective, randomized trials are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. Clinical use of a novel in vivo 4D monitoring system for simultaneous patient motion and dose measurements
- Author
-
Cherpak, Amanda J., Cygler, Joanna E., Andrusyk, Steve, Pantarotto, Jason, MacRae, Robert, and Perry, Gad
- Subjects
- *
ELECTROMAGNETISM , *LUNG cancer patients , *CANCER treatment , *ACQUISITION of data , *EXPERIMENTS ,CANCER diagnostic equipment - Abstract
Abstract: Purpose: A new 4D in vivo dosimetry tool, RADPOS, has been used on lung cancer patients to evaluate the feasibility of using the detectors to characterize variations in patient breathing patterns as well as to monitor daily variations in dose. Methods and materials: The RADPOS system combines a MOSFET dosimeter with an electromagnetic positioning sensor for simultaneous measurement of real-time dose and spatial coordinates. Three RADPOS sensors were placed on patients’ chest and abdomen during a 4DCT and daily treatments. A fourth detector was also placed on the couch as reference. Position data were collected in real-time and total dose was read at the end of each fraction. Results: Significant deviations in surface motion have been found between the day of 4DCT and treatment fractions in 9 of 10 patients. Variations in daily dose ranged from 2.5 to 13.7cGy (2.8–14.0%) and results agreed with treatment plan values for all but three points. Conclusions: Changes in breathing motion have been found that emphasize a need for continued position monitoring. RADPOS measurements can be used to monitor such variations as well as to measure surface dose without any disruption to the treatment schedule or discomfort to patients. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
5. 236: Validity of Specific Growth Rate in Stage I Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy (SBRT).
- Author
-
Atallah, Soha, Cook, Graham, MacRae, Robert, Cross, Peter, Bezjak, Andrea, Hope, Andrew J., and Pantarotto, Jason
- Subjects
- *
STEREOTACTIC radiotherapy , *CANCER treatment , *NON-small-cell lung carcinoma , *TUMOR growth , *CONFERENCES & conventions - Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.